Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
Gastritis, Dyspepsia, Helicobacter Pylori Infection
About this trial
This is an interventional treatment trial for Gastritis focused on measuring Helicobacter pylori, High-dose dual therapy, Bismuth-combining quadruple therapy, Intestinal Microecology
Eligibility Criteria
Inclusion Criteria: Age 18 to 70 years, regardless of gender. Patients with definite Hp infection (positive for either 13C/14C urea breath test, rapid urease test, and fecal Hp antigen test) and who have not received H. pylori eradication therapy. Voluntary Hp eradication therapy. Women of childbearing potential are required to use a medically advisable form of contraception during the trial and for 30 days after the trial ends. Exclusion Criteria: Patients who have had a definite diagnosis of Hp infection and have been treated with antibiotic eradication therapy. Patients with contraindications to or allergies to the study drug. Patients with severe organ damage and complications (e.g., cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine disease Continuous use of anti-ulcer drugs, antibiotics or bismuth complexes (taken at least 2 weeks prior to the screening for Hp infection) Pregnant and lactating women. Having undergone upper gastrointestinal surgery. Have symptoms of dysphagia. Evidence of bleeding or iron deficiency anemia. History of malignancy. History of drug or alcohol abuse within the last 1 year. Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except for the use of aspirin ≤100 mg/d) Those with psychiatric disorders. Received other clinical trials within the past 3 months Refusal to sign the informed consent form.
Sites / Locations
- Xijing Hosipital of Digestive DiseaseRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High-dose dual therapy
Bismuth Quadruple Therapy
Esomeprazole Enteric Tablets 40mg, 3 times/day; Amoxicillin Capsules 1000mg, 3 times/day.The course of all drugs is two weeks.
Esomeprazole Enteric Tablets 40mg, 2 times/day; Amoxicillin Capsules 1000mg, 2 times/day; Clarithromycin Tablets 500mg, 2 times/day; Colloidal Bismuth Tartrate Capsules 220mg, 2 times/day.The course of all drugs is two weeks.